Did Orasure Technologies beat or miss consensus estimates last quarter?

What guidance did Orasure Technologies's management provide for the next earnings period?

What were the key takeaways from Orasure Technologies's earnings call?

What is the market's earnings forecast for Orasure Technologies next quarter?

What factors drove the changes in Orasure Technologies's revenue and profit?

What does Orasure Technologies do and what are its main business segments?

What is the revenue and EPS growth rate for Orasure Technologies year over year?

What is Orasure Technologies's latest dividend and current dividend yield?

- **Revenue Performance**: Q3 core revenue $27 million, with Diagnostics and Sample Management stable amid market challenges.
- **Strategic Acquisition**: BioMedomics adds Sickle SCAN, targeting underserved markets with potential for $1-3 million annual revenue growth.
- **Cost Efficiency**: Improved gross margin (43.5%) and disciplined OpEx, enabling $10 million Q4 innovation investment.
- **Pipeline Momentum**: Sherlock CT/NG submission expected in late 2025, alongside proteomics and STI product launches.
- **Financial Strength**: $216 million cash, no debt, and disciplined capital deployment.

**【CEO Summary Section】**
- **Q3 2025 Financials**: Total revenue of $27.1 million, with core revenue at $27.0 million. Diagnostics contributed $14.5 million, and Sample Management $10.3 million.
- **International Diagnostics**: Anticipated 20% revenue decline in 2025 due to inventory challenges, with BioMedomics acquisition adding Sickle SCAN for underserved markets.
- **U.S. Diagnostics**: Expansion into non-public health markets (e.g., urgent care, correctional facilities) and renewal of Together Take Me Home program, adding $1.8 million in Q4.
- **Sample Management**: Flat year-over-year revenue but poised for growth in 2026; collaboration with ENDO 1000 project for endometriosis research.
- **Innovation Pipeline**: Launch of HEMAcollect PROTEIN for proteomics, Colli-Pee for STI testing, and Sherlock CT/NG platform in late 2025/early 2026.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP operating loss of $16.1 million, non-GAAP loss of $12.7 million. Gross margin 43.5% (44.2% non-GAAP), driven by lower scrap costs.
- **Balance Sheet**: $216 million cash, no debt. $5 million share repurchase and $10 million Q4 innovation investment (Sherlock platform).
- **Q4 Guidance**: Revenue $25-28 million, lower gross margin due to international mix.

**【Q&A Highlights】**
- **BioMedomics Acquisition**: $4 million upfront, potential contingent consideration. Expected to be cash flow breakeven with attractive ROI via OTI's existing channels.
- **Cost Management**: Lower scrap expenses and efficient OpEx allocation, with core business breakeven and innovation-focused spending.
- **In-Sourcing Impact**: No lingering costs; operational efficiencies maintained.


OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

OSUR

OSUR fundamentals

You can ask Aime